In 20% of HCC patients, pembrolizumab has shown efficacy in rejuvenating exhausted T cells and restoring their antitumor functions by inhibiting the PD-1 pathway (21, 22). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.